23Andme Holding Co

NASDAQ:ME USA Diagnostics & Research
Market Cap
$11.96 Million
Market Cap Rank
#28621 Global
#9526 in USA
Share Price
$0.61
Change (1 day)
-21.26%
52-Week Range
$0.53 - $1.84
All Time High
$353.00
About

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic a… Read more

23Andme Holding Co (ME) - Total Assets

Latest total assets as of December 2024: $277.42 Million USD

Based on the latest financial reports, 23Andme Holding Co (ME) holds total assets worth $277.42 Million USD as of December 2024.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

23Andme Holding Co - Total Assets Trend (2019–2024)

This chart illustrates how 23Andme Holding Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

23Andme Holding Co - Asset Composition Analysis

Current Asset Composition (March 2024)

23Andme Holding Co's total assets of $277.42 Million consist of 63.4% current assets and 36.6% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 54.8%
Accounts Receivable $9.07 Million 2.3%
Inventory $12.46 Million 3.2%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $53.77 Million 13.6%
Goodwill $0.00 0.0%

Asset Composition Trend (2019–2024)

This chart illustrates how 23Andme Holding Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: 23Andme Holding Co's current assets represent 63.4% of total assets in 2024, a decrease from 73.8% in 2019.
  • Cash Position: Cash and equivalents constituted 54.8% of total assets in 2024, down from 65.0% in 2019.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2019.
  • Asset Diversification: The largest asset category is intangible assets at 13.6% of total assets.

23Andme Holding Co Competitors by Total Assets

Key competitors of 23Andme Holding Co based on total assets are shown below.

Company Country Total Assets
ADCNF
OTCGREY:ADCNF
USA $4.51 Billion
Berry Genomics Co Ltd
SHE:000710
China CN¥2.34 Billion
Malaysian Genomics Resource
KLSE:0155
Malaysia RM20.70 Million
NSN Co. Ltd
KQ:031860
Korea ₩60.96 Billion
JOONGANG DNM Co.Ltd
KQ:051980
Korea ₩121.79 Billion
GeneMatrix Inc
KQ:109820
Korea ₩28.03 Billion
Genoray Co. Ltd
KQ:122310
Korea ₩125.67 Billion
Green Cross Lab Cell Corporation
KQ:144510
Korea ₩565.79 Billion

23Andme Holding Co - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.24 - 0.75

Moderate asset utilization - 23Andme Holding Co generates 0.56x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -168.71% - -18.88%

Negative ROA - 23Andme Holding Co is currently not profitable relative to its asset base.

23Andme Holding Co - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.05 2.15 0.20
Quick Ratio 0.91 2.04 0.20
Cash Ratio 0.00 0.00 0.00
Working Capital $8.24 Million $ 165.82 Million $ -102.13K

23Andme Holding Co - Advanced Valuation Insights

This section examines the relationship between 23Andme Holding Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.62
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) -58.1%
Total Assets $395.17 Million
Market Capitalization $9.76 Million USD

Valuation Analysis

Below Book Valuation: The market values 23Andme Holding Co's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: 23Andme Holding Co's assets decreased by 58.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for 23Andme Holding Co (2019–2024)

The table below shows the annual total assets of 23Andme Holding Co from 2019 to 2024.

Year Total Assets Change
2024-03-31 $395.17 Million -58.08%
2023-03-31 $942.60 Million -18.18%
2022-03-31 $1.15 Billion +154.83%
2021-03-31 $452.10 Million +11.73%
2020-03-31 $404.63 Million -41.92%
2019-03-31 $696.68 Million --